{"denomUnitsSelected":"Participants","description":"Will be compared between Arms A and B.","reportingStatus":"NOT_POSTED","timeFrame":"From day 1 of liposome-encapsulated daunorubicin-cytarabine until no response is achieved, relapse or death, will be assessed for up to 5 years","title":"Event-free Survival","type":"SECONDARY"}